Barthélemy, Nicolas R.
,
Li, Yan
Joseph-Mathurin, Nelly
Gordon, Brian A. http://orcid.org/0000-0003-2109-2955
Hassenstab, Jason
Benzinger, Tammie. L. S. http://orcid.org/0000-0002-8114-0552
Buckles, Virginia
Fagan, Anne M.
Perrin, Richard J.
Goate, Alison M. http://orcid.org/0000-0002-0576-2472
Morris, John C.
Karch, Celeste M. http://orcid.org/0000-0002-6854-5547
Xiong, Chengjie
Allegri, Ricardo
Mendez, Patricio Chrem
Berman, Sarah B.
Ikeuchi, Takeshi http://orcid.org/0000-0001-8828-8085
Mori, Hiroshi
Shimada, Hiroyuki
Shoji, Mikio
Suzuki, Kazushi
Noble, James
Farlow, Martin
Chhatwal, Jasmeer http://orcid.org/0000-0002-7792-1698
Graff-Radford, Neill R.
Salloway, Stephen
Schofield, Peter R. http://orcid.org/0000-0003-2967-9662
Masters, Colin L.
Martins, Ralph N.
O’Connor, Antoinette
Fox, Nick C.
Levin, Johannes
Jucker, Mathias http://orcid.org/0000-0001-9045-1072
Gabelle, Audrey
Lehmann, Sylvain
Sato, Chihiro
Bateman, Randall J.
McDade, Eric http://orcid.org/0000-0002-6764-3866
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (UF1AG032438, K23 AG046363, UF1AG032438, K23 AG046363, K23 AG046363, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, UF1AG032438, MR/L023784/1)
Alzheimer’s Association (AARF-16-443265)
Raul Carrea Institute for Neurological Research
Development Grants for Dementia from Japan Agency for Medical Research and Development
RCUK | Medical Research Council (MR/009076/1, UF1AG032438, MR/L023784/1, MR/009076/1, UF1AG032438)
Deutsches Zentrum für Neurodegenerative Erkrankungen (UF1AG032438, UF1AG032438)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS095773)
BrightFocus Foundation (A20143845)
Fondation du Plan Alzheimer
Article History
Received: 11 May 2019
Accepted: 30 January 2020
First Online: 11 March 2020
Competing interests
: R.J.B. has equity ownership interest in C2N Diagnostics and receives royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University, with R.J.B., E.M. and N.R.B. as co-inventors, has submitted the US nonprovisional patent application ‘Cerebrospinal fluid (CSF) tau rate of phosphorylation measurement to define stages of Alzheimer’s disease and monitor brain kinases/phosphatases activity’. R.J.B. has received honoraria from Janssen and Pfizer as a speaker, and from Merck and Pfizer as an advisory board member. E.M. has received royalty payments for an educational program supported by Eli Lilly and as a member of a scientific advisory board for Eli Lilly.